Company intelligence / Profile preview

EB FSD

Toronto, Ontario, Canada

Ownership: Private
Employees: ~25
Development stage: Other

Overview

FSD Pharma is a biopharmaceutical company focused on developing novel treatments for neurodegenerative disorders, inflammatory diseases, and pain management. The company's lead candidate, Lucid-21-302 (Lucid-MS), is a first-in-class small molecule being developed for the treatment of Multiple Sclerosis. Additionally, FSD Pharma has explored the use of ultra-micronized palmitoylethanolamide (PEA) for various inflammatory conditions, including Epidermolysis Bullosa (EB). The company operates through its subsidiaries, FSD BioSciences and Lucid Psycheceuticals, to advance its diverse pipeline of neuro-active and anti-inflammatory compounds.

Therapeutic areas: GastroenterologyPulmonologyDermatologyNeurologyRheumatology
Modalities: Small moleculeBiologicPeptides
Industry: Biotech

Partnerships

SciCann Therapeutics

Beyond the preview

Go deeper on EB FSD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB FSD.

Explore the full profile